Two Sigma Advisers
CLSD

Two Sigma Advisers’s Clearside Biomedical CLSD Stock Holding History

Two Sigma Advisers’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,193
Closed -$54.7K – 2520
2023
Q3 		$54.7K Sell
4,193
-2,480
-37% -$37.6K ﹤0.01% 2270
2023
Q2 		$112K Sell
6,673
-1,074
-14% -$18.5K ﹤0.01% 2196
2023
Q1 		$121K Sell
7,747
-3,453
-31% -$67.1K ﹤0.01% 2355
2022
Q4 		$188K Sell
11,200
-3,667
-25% -$66K ﹤0.01% 2204
2022
Q3 		$252K Sell
14,867
-9,260
-38% -$203K ﹤0.01% 2124
2022
Q2 		$532K Sell
24,127
-19,760
-45% -$480K ﹤0.01% 1890
2022
Q1 		$1.51M Sell
43,887
-14,773
-25% -$442K ﹤0.01% 1411
2021
Q4 		$2.42M Sell
58,660
-8,767
-13% -$568K 0.01% 1096
2021
Q3 		$6.07M Buy
67,427
+1,427
+2% +$126K 0.02% 698
2021
Q2 		$4.82M Buy
66,000
+22,547
+52% +$1.05M 0.01% 877
2021
Q1 		$1.61M Buy
43,453
+40,133
+1,209% +$2.02M ﹤0.01% 1382
2020
Q4 		$136K Sell
3,320
-3,553
-52% -$92.2K ﹤0.01% 2231
2020
Q3 		$159K Buy
+6,873
New +$178K ﹤0.01% 2203
2019
Q2 		– Sell
-1,333
Closed -$28K – 2332
2019
Q1 		$28K Buy
+1,333
New +$26.5K ﹤0.01% 2250
2018
Q2 		– Sell
-760
Closed -$122K – 2379
2018
Q1 		$122K Buy
+760
New +$92.6K ﹤0.01% 2209

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Two Sigma Advisers's CLSD Position: Q4 2023 in Review

Two Sigma Advisers sold out of Clearside Biomedical (CLSD) in Q4 2023, closing a stake of 4,193 shares — an estimated $54.7K sold.

Two Sigma Advisers first reported a position in CLSD in Q1 2018 and held it in 15 quarters. The position peaked at $6.07M in Q3 2021. 46 funds tracked by Wall St. Rank hold CLSD as of Q4 2023.

  • Two Sigma Advisers reported no remaining Clearside Biomedical position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 4,193 Clearside Biomedical shares in Q4 2023, an estimated $54.7K.
  • Two Sigma Advisers first reported a position in Clearside Biomedical in Q1 2018 and held it in 15 quarters.
  • Two Sigma Advisers's Clearside Biomedical position peaked at $6.07M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2023.

Based on Two Sigma Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.